CN116528904A - 放射性药物和方法 - Google Patents

放射性药物和方法 Download PDF

Info

Publication number
CN116528904A
CN116528904A CN202180053207.3A CN202180053207A CN116528904A CN 116528904 A CN116528904 A CN 116528904A CN 202180053207 A CN202180053207 A CN 202180053207A CN 116528904 A CN116528904 A CN 116528904A
Authority
CN
China
Prior art keywords
dottate
amount
compounds
lutetium
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180053207.3A
Other languages
English (en)
Chinese (zh)
Inventor
乔·麦肯
贾斯蒂娜·凯利
保罗·比隆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Probo Development Business Center
Original Assignee
Probo Development Business Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probo Development Business Center filed Critical Probo Development Business Center
Publication of CN116528904A publication Critical patent/CN116528904A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180053207.3A 2020-08-27 2021-08-27 放射性药物和方法 Pending CN116528904A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063071138P 2020-08-27 2020-08-27
US63/071,138 2020-08-27
PCT/IB2021/000589 WO2022043754A2 (en) 2020-08-27 2021-08-27 Radiopharmaceutical and methods

Publications (1)

Publication Number Publication Date
CN116528904A true CN116528904A (zh) 2023-08-01

Family

ID=80352743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180053207.3A Pending CN116528904A (zh) 2020-08-27 2021-08-27 放射性药物和方法

Country Status (9)

Country Link
US (2) US11439714B2 (cg-RX-API-DMAC7.html)
EP (1) EP4204011A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023540240A (cg-RX-API-DMAC7.html)
KR (1) KR20240121161A (cg-RX-API-DMAC7.html)
CN (1) CN116528904A (cg-RX-API-DMAC7.html)
AU (1) AU2021330382A1 (cg-RX-API-DMAC7.html)
CA (1) CA3190855A1 (cg-RX-API-DMAC7.html)
TW (1) TW202227143A (cg-RX-API-DMAC7.html)
WO (1) WO2022043754A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
EP4178628A4 (en) 2020-07-13 2025-04-02 Point Biopharma, Inc. RADIOPHARMACEUTICALS AND PROCEDURES
JP2025505307A (ja) * 2022-03-02 2025-02-21 ポイント・バイオファーマ・インコーポレイテッド 放射性医薬品及び方法
CN115015441B (zh) * 2022-07-14 2023-08-18 原子高科股份有限公司 一种测定镥[177Lu]氧奥曲肽注射液中稳定剂含量的方法
US12514939B2 (en) 2024-02-14 2026-01-06 Alpha-9 Oncology, Inc. Stable radiopharmaceutical compositions and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200030467A1 (en) * 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) Srl Stable, concentrated radionuclide complex solutions
WO2020088767A1 (en) * 2018-10-31 2020-05-07 Advanced Accelerator Applications (Italy) Srl Methods for synthesis of radionuclide complex

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1096278A (en) 1913-08-25 1914-05-12 American Radiator Co Service-outlet fitting for pneumatic cleaning systems.
US6066309A (en) 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6358245B1 (en) 1998-02-19 2002-03-19 Curon Medical, Inc. Graphical user interface for association with an electrode structure deployed in contact with a tissue region
US7297143B2 (en) 2003-02-05 2007-11-20 Arthrocare Corporation Temperature indicating electrosurgical apparatus and methods
JP5139678B2 (ja) 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
JP2018518526A (ja) * 2015-06-25 2018-07-12 アドバンスド アクセレレーター アプリケーションズ ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法
CA3035415A1 (en) 2016-05-23 2017-11-30 Imperial Innovations Limited Surgical instrument, robotic arm and control system for a robotic arm
US10537399B2 (en) 2016-08-16 2020-01-21 Ethicon Llc Surgical tool positioning based on sensed parameters
US10537394B2 (en) 2016-12-19 2020-01-21 Ethicon Llc Hot device indication of video display
US10596276B2 (en) * 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
WO2020064693A1 (en) * 2018-09-25 2020-04-02 Advanced Accelerator Applications (Italy) Srl Combination therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200030467A1 (en) * 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) Srl Stable, concentrated radionuclide complex solutions
WO2020088767A1 (en) * 2018-10-31 2020-05-07 Advanced Accelerator Applications (Italy) Srl Methods for synthesis of radionuclide complex

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARCHANA MUKHERJEE等: "Single vial kit formulation of DOTATATE for preparation of 177Lu-labeled therapeutic radiopharmaceutical at hospital radiopharmacy", 《JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS》, vol. 58, no. 4, 30 April 2015 (2015-04-30), pages 166 - 172 *
TAPAS DAS等: "Preparation of Patient Doses of 177Lu-DOTA-TATE Using Indigenously Produced 177Lu: The Indian Experience", 《CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS》, vol. 26, no. 3, 31 May 2011 (2011-05-31), pages 395 - 400 *

Also Published As

Publication number Publication date
JP2023540240A (ja) 2023-09-22
AU2021330382A1 (en) 2023-05-04
KR20240121161A (ko) 2024-08-08
US11439714B2 (en) 2022-09-13
US20220062447A1 (en) 2022-03-03
US20220387637A1 (en) 2022-12-08
CA3190855A1 (en) 2022-03-03
TW202227143A (zh) 2022-07-16
EP4204011A4 (en) 2025-06-18
WO2022043754A2 (en) 2022-03-03
WO2022043754A3 (en) 2022-04-07
EP4204011A2 (en) 2023-07-05
AU2021330382A9 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
CN116528904A (zh) 放射性药物和方法
US20230302163A1 (en) Radiopharmaceutical and methods
US11129912B1 (en) Radiopharmaceutical and methods
CN118267495A (zh) 一种靶向HER2的rk多肽放射性药物及其制备方法
JP7804652B2 (ja) ６４Ｃｕ－ＤＯＴＡＴＡＴＥのスケールアップのための放射標識および製剤化
CN116547007A (zh) 放射性药物和方法
Chen et al. GMP-compliant automated radiosynthesis of [18F] SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2 A (SV2A)
HK40088578A (zh) 放射性药物和方法
KR20240155937A (ko) 방사성제약 및 방법
CN118742332A (zh) 放射性药物和方法
US11723992B2 (en) Method for extraction and purification of 68GA
CN119874752A (zh) 一种Al18F标记的PSMA放射性药物、制备方法及其应用
WO2021108474A1 (en) Method for extraction and purification of ai18f-labeled hbed conjugates
LijuanáChen et al. GMP-compliant automated radiosynthesis of [18 F] SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2áA (SV2A)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40088578

Country of ref document: HK